Interestingly, the activity of DDA on AML patient samples did not correlate with the cytogenetic risk, clonogenic properties, white blood cell count or FLT3-ITD and NPM1 mutational status (Fig. 7f–i). The gene discussed is NPM1; the disease is acute myeloid leukemia.